BioXcel Therapeutics, Inc. — Investor Relations & Filings
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company that utilizes a proprietary artificial intelligence (AI) platform for drug development. The company focuses on creating transformative medicines in the fields of neuroscience and immuno-oncology. Its AI-driven approach aims to identify new therapeutic uses for existing molecules and novel compounds, potentially accelerating development timelines. The company's lead commercial product is IGALMI™ (dexmedetomidine sublingual film), approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel's late-stage clinical pipeline includes programs investigating treatments for agitation in patients with Alzheimer's disease and other neuropsychiatric conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 8-K | 2026-05-15 | English | |
| 10-Q | 2026-05-15 | English | |
| 8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-04-17 | English | |
| 8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-04-01 | English | |
| 10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-03-27 | English | |
| 8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-03-27 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46352908 | FORM 8-K | 2026-05-15 | English | ||
| 46352910 | 10-Q | 2026-05-15 | English | ||
| 34662692 | 8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-04-17 | English | ||
| 33133861 | 8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-04-01 | English | ||
| 33066130 | 10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-03-27 | English | ||
| 33058444 | 8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer) | 2026-03-27 | English | ||
| 31461143 | 8-K Filing | 2026-02-12 | English | ||
| 31461095 | SCHEDULE 13G/A Filing | 2026-02-09 | English | ||
| 31461094 | 8-K Filing | 2026-02-06 | English | ||
| 31461111 | 8-K Filing | 2026-01-20 | English | ||
| 13071274 | OWNERSHIP DOCUMENT | 2026-01-13 | English | ||
| 13071275 | OWNERSHIP DOCUMENT | 2026-01-13 | English | ||
| 13071276 | OWNERSHIP DOCUMENT | 2026-01-13 | English | ||
| 13071277 | OWNERSHIP DOCUMENT | 2026-01-13 | English | ||
| 13071278 | OWNERSHIP DOCUMENT | 2026-01-13 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Amylyx Pharmaceuticals, Inc.
Develops therapies for neurodegenerative diseases and other…
|
AMLX | US | Manufacturing |
|
AN2 Therapeutics, Inc.
Biopharmaceutical firm developing boron-based drugs for inf…
|
ANTX | US | Manufacturing |
|
Ananda Pharma Plc
Biopharmaceutical firm developing cannabinoid-based medicin…
|
ANAN | GB | Manufacturing |
|
ANATOLİA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş.
Designs, develops, and manufactures molecular diagnostic so…
|
ANGEN | TR | Manufacturing |
|
ANAVEX LIFE SCIENCES CORP.
Clinical-stage biopharmaceutical company developing therape…
|
AVXL | US | Manufacturing |
|
Anbio Biotechnology
Develops and provides in-vitro diagnostic (IVD) solutions a…
|
NNNN | KY | Manufacturing |
|
Anebulo Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for acute canna…
|
ANEB | US | Manufacturing |
|
AnGes, Inc.
Biopharmaceutical firm developing gene-based and nucleotide…
|
4563 | JP | Manufacturing |
|
ANG Lifesciences India Limited
Develops and manufactures sterile dry powder and liquid inj…
|
540694 | IN | Manufacturing |
|
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.
Develops biopharmaceuticals, genetic engineering products, …
|
300009 | CN | Manufacturing |
BioXcel Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34564/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34564 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34564 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34564 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34564}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BioXcel Therapeutics, Inc. (id: 34564)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.